03Apr
03Apr
Corbus Announces Dosing of First Patient in U.S. Phase 1 Clinical Trial of Its Next Generation Nectin-4 Targeting ADC
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), a precision oncology company with a diversified portfolio, announced today the first patient in the U.S. has been dosed in the Phase 1 clinical trial of CRB-701 (SYS6002), a next-generation antibody-drug-conjugate (ADC) targeting Nectin-4. The Phase 1 portion of the open label study design (NCT06265727), being conducted in the U.S. and Europe, will evaluate the safety, efficacy and pharmacokinetics (PK) of CRB-701 in participants with advanced solid tumors associated with...
02Apr
2024 Manufacturing Excellence Awards
The entire Central Massachusetts manufacturing industry has stayed surprisingly similar to its original role in the region. With $6.3 billion in annual economic output, manufacturing remains the largest industry in Central Massachusetts, according to the U.S. Bureau of Economic Analysis. This is why Worcester Business Journal chooses to honor the industry with our annual Manufacturing Excellence Awards, which are in their ninth year. WBJ likes to take a moment each year to highlight the best of the best. In addition...
02Apr